Filing Details

Accession Number:
0000899243-20-031681
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-19 17:44:40
Reporting Period:
2020-11-17
Accepted Time:
2020-11-19 17:44:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1640455 Jounce Therapeutics Inc. JNCE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1591092 Cary Pfeffer C/O Third Rock Ventures, Llc,
29 Newbury Street, 3Rd Floor
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-11-17 0 $0.00 0 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,917 Direct
Footnotes
  1. On November 17, 2020, Third Rock Ventures II, L.P. ("TRV II") sold 15,000 shares of Common Stock of the Issuer at a price per share of $7.2515.
  2. After the above transaction, TRV II owned 9,215,349 shares of Common Stock of the Issuer.
  3. The Reporting Person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of TRV II. The Reporting Person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
  4. Third Rock Ventures III, L.P. ("TRV III") directly holds 3,048,780 shares of the Issuer's Common Stock. The Reporting Person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of TRV III. The Reporting Person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.